AKT1 and central nervous system cancer: In high-grade gliomas, determinants for EGFR tyrosine kinase inhibitor sensitivity, such as gene copy number, EGFR or EGFRvIII proteins expression, low phospho-Akt expression or PTEN loss have been investigated [25]–[28], overall with inconsistent results.